›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:SOPHiA Myeloid Plus Solution
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sophia GeneticsType:
Laboratory Developed Test
Related tests:
SOPHiA Myeloid Plus Solution is a ready-to-use genomic application that enables accurate characterization of DNA and RNA-based fusions associated with different blood cancers. This comprehensive solution accurately covers 30 genes already covered in the SOPHiA Myeloid Solution and 119 RNA-based fusions associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. The application combines a capture-based target enrichment kit with the advanced analytical capabilities of the SOPHiA DDM™ platform, providing high-quality and reproducible data through a streamlined workflow from sample to report. Through a streamlined, customizable, and scalable NGS-based workflow, SOPHiA Myeloid Plus Solution reduces turnaround time and improves the efficiency of assessing complex variants associated with different blood cancers.
Cancer:
Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Gene:
ABL1 (ABL proto-oncogene 1), ASXL1 (ASXL Transcriptional Regulator 1), BRAF (B-raf proto-oncogene), CALR (Calreticulin), CBL (Cbl proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha)
See More ...
ABL1 (ABL proto-oncogene 1), ASXL1 (ASXL Transcriptional Regulator 1), BRAF (B-raf proto-oncogene), CALR (Calreticulin), CBL (Cbl proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), CSF3R (Colony Stimulating Factor 3 Receptor), DNMT3A (DNA methyltransferase 1), ETV6 (ETS Variant Transcription Factor 6), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FLT3 (Fms-related tyrosine kinase 3), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), NPM1 (Nucleophosmin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), RUNX1 (RUNX Family Transcription Factor 1), SETBP1 (SET Binding Protein 1), SF3B1 (Splicing Factor 3b Subunit 1), SRSF2 (Serine and arginine rich splicing factor 2), TET2 (Tet Methylcytosine Dioxygenase 2), TP53 (Tumor protein P53), U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), WT1 (WT1 Transcription Factor), ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
Method:
Next-Generation Sequencing (NGS)
